on TRANSGENE (EPA:TNG)
Transgene and ProBioGen join forces for personalized cancer vaccines
French biotech Transgene and German ProBioGen are partnering to accelerate the development of therapeutic cancer vaccines. The collaboration aims to integrate ProBioGen’s innovative AGE1.CR.pIX® cell line into Transgene’s production of individualized vaccines. Focused on process optimization, this approach is expected to improve manufacturing profitability and efficiency.
AGE1.CR.pIX® is distinguished by its genetic stability and high yield, already proven in Phase III. Transgene hopes to promote individualized medicine, with vaccine solutions specific to each patient. The partnership marks a significant advance in the personalized approach to cancer treatment, offering new perspectives to patients.
R. H.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all TRANSGENE news